We use a scan and read method of research, with all of the Companies we follow. We first scan headlines and then we re-post press releases that we find interesting, typically going back three years.
We next do the same with Quarterly filings, 8K’s and 10Ks. Then we do same with media reports and or mentions – including videos. Finally we scan for and post here, all third-party research reports, including ours.
When we post, we add a summary to the post. We update this page weekly.
For organizational purposes, we date all posts newest first, for easy future reference.
- September 15, 2025: Report: Initiating Coverage on Nutriband (NTRB) $7.00. Biotech Stock Review.
- September 12, 2025: Research Report (UPDATE). Noble Securities, $15 Price Target
- September 3, 2025: Warrant Exercise. Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000.
- April 30, 2025: CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024.
- Jan 22, 2025: Research Report (INITIATION). Noble Securities, $15 Price Target.
September 15, 2025: Report: Initiating Coverage on Nutriband (NTRB) $7.00. Biotech Stock Review.
This could be one of our most interesting ideas ever. Simple story, simple cap table – and while Nutriband is not heavily funded, it’s funded enough – to get them through the upcoming trials.
The FDA trials (called HAL trials) are within striking distance – meaning not three to four years out. Compared to, let’s call them ‘standard trials,’ which can take years. The trial requirements are additionally small (around 100 patients) and projected to be inexpensive – under $5 million, compared to $10’s or even $100’s of million.
We’ve been through all and it’s aways stressful when a company is facing a $100 million trial, even if they have $50 million in the bank. Like a ticking time bomb.
September 12, 2025: Research Report (UPDATE). Noble Securities, $15 Price Target
Conclusion. The company continues to use increasing revenues from contract manufacturing to offset the cost of developing the AVERSA technology. This has kept the share base and accumulated deficit low. We view AVERSA Fentanyl as an important new product that can reduce abuse potential, while its improved safety can help patients get the effective pain relief they need. We are reiterating our Outperform rating and $15 price target.
Sept 03, 2025: Warrant Exercise. Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000.
Announced today that it has seen warrants exercised at a strike price of $6.43 for proceeds to the company of $5,306,000.
Read More
April 30, 2025: CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024.
AVERSA Fentanyl has the potential to become the world’s first opioid pain patch with abuse deterrent properties and is estimated to potentially reach peak annual sales of $80M – $200M. In addition, AVERSA Buprenorphine, our next candidate for AVERSA is projected to reach peak annual sales of $70M – $130M. Nutriband recently performed an extensive evaluation of the commercial cost of goods of incorporating the Aversa technology into existing FDA-approved transdermal patches and have confirmed the viability of achieving high margins that are typically found in NDA pharmaceutical products.
Jan 22, 2025: Research Report (INITIATION). Noble Securities, $13 Price Target.
Conclusion. We believe the Phase 1 clinical trial will show sufficient abuse deterrence to allow for Nutriband to file a New Drug Application using the 505(b)(2) pathway for approval in 2H25. We have allowed for a 10-month standard review, although Priority Review could potentially shorten review time to 6 months.
We anticipate approval in 2H26. We base our valuation on FY2027 EPS of $1.45 per share discounted at 30% per year and apply a multiple of 15X for a price target of $13 per share.
Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market.
Nutriband also announced the pricing of an underwritten public offering of 1,056,000 units of securities at a public offering price of $6.25 per unit for total gross proceeds of $6.6 million.
“Uplisting onto the Nasdaq Capital Market is a significant milestone in our evolution, and we believe will exponentially increase our corporate visibility and broaden the awareness of Nutriband amongst active market participants,” said Gareth Sheridan, CEO. “This achievement reflects the hard work of our outstanding team, and we look forward to continuing to execute on our strategic plan and growth initiatives as we build long term shareholder value.”
READ MORE
